2000
Autoimmune mechanisms in movement disorders
Visvanathan K, Trifiletti R, Altemus M, Zabriskie J. Autoimmune mechanisms in movement disorders. Seminars In Pediatric Neurology 2000, 7: 103-107. PMID: 10914411, DOI: 10.1053/pb.2000.6694.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAutoantibodiesBiomarkersB-LymphocytesBrainHumansMovement DisordersNeuronsObsessive-Compulsive DisorderPlasmapheresisTourette SyndromeConceptsObsessive-compulsive disorderTourette syndromeGilles de la Tourette's syndromeAnti-brain antibodiesChildhood-onset obsessive-compulsive disorderB-cell markersLa Tourette's syndromeNumber of disordersAutoimmune mechanismsSydenham's choreaPsychiatric manifestationsStreptococcal antigensMovement disordersPathological mechanismsNeuropsychiatric disordersDisordersNeuropsychiatric diagnosesFurther molecular characterizationCompulsive disorderChoreaPerceptual dysfunctionSyndromeDiseaseNeurophysiological processesRecent findings
1999
Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder
Bengel D, Greenberg B, Corá-Locatelli G, Altemus M, Heils A, Li Q, Murphy D. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder. Molecular Psychiatry 1999, 4: 463-466. PMID: 10523819, DOI: 10.1038/sj.mp.4000550.Peer-Reviewed Original ResearchMeSH KeywordsAllelesCarrier ProteinsCase-Control StudiesChi-Square DistributionFemaleGene FrequencyGenetic LinkageGenetic Predisposition to DiseaseGenotypeHumansMaleMembrane GlycoproteinsMembrane Transport ProteinsNerve Tissue ProteinsObsessive-Compulsive DisorderPolymorphism, GeneticPromoter Regions, GeneticSerotonin Plasma Membrane Transport ProteinsWhite PeopleConceptsObsessive-compulsive disorderRecent family-based studyCentral serotonergic systemTreatment of OCDNon-patient control groupSerotonergic agentsSerotonin reuptakeCaucasian patientsSerotonergic neurotransmissionSerotonergic systemControl groupFamily-based studyFunctional polymorphismsSerotonin transporterRegulatory region polymorphismKey modulatorPatientsRegion polymorphismsDisordersLong allelePolymorphismAssociationPreliminary studyOpen trial of flutamide for treatment of obsessive-compulsive disorder.
Altemus M, Greenberg B, Keuler D, Jacobson K, Murphy D. Open trial of flutamide for treatment of obsessive-compulsive disorder. The Journal Of Clinical Psychiatry 1999, 60: 442-5. PMID: 10453797, DOI: 10.4088/jcp.v60n0704.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAndrogen receptorEstrogen receptorClassical intracellular androgen receptorsOCD symptomsPrimary outcome measureFuture treatment trialsIntracellular androgen receptorHamilton Rating ScaleGonadal steroid hormonesAndrogen receptor antagonistYale-Brown Obsessive Compulsive ScaleEffect of treatmentBeck Anxiety InventoryLack of responseObsessive Compulsive ScaleOpen trialTreatment trialsReceptor antagonistGonadal steroidsOutcome measuresCompetitive antagonistEstrogen activityFlutamideSteroid hormonesNormal CSF oxytocin and NPY levels in OCD
Altemus M, Jacobson K, Debellis M, Kling M, Pigott T, Murphy D, Gold P. Normal CSF oxytocin and NPY levels in OCD. Biological Psychiatry 1999, 45: 931-933. PMID: 10202583, DOI: 10.1016/s0006-3223(98)00263-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase-Control StudiesFemaleHumansMaleMiddle AgedNeuropeptide YObsessive-Compulsive DisorderOxytocinSex FactorsConceptsObsessive-compulsive disorderNPY levelsCSF levelsOCD patientsCSF oxytocinCentral nervous system neuropeptidesIncreased CSF levelsHealthy normal volunteersControl subjectsNPY regulationNormal volunteersHigher CSFSymptom profilesControl groupPatientsPotential mediatorsNeuropeptidesOxytocinSignificant differencesNPYCSFLevelsPrior findingsAbnormalities
1998
Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients
Greenberg B, Benjamin J, Martin J, Keuler D, Huang S, Altemus M, Murphy D. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology 1998, 140: 434-444. PMID: 9888619, DOI: 10.1007/s002130050787.Peer-Reviewed Original ResearchConceptsFluoxetine-treated patientsObsessive-compulsive disorderUnmedicated patientsAdministration of metergolineSerotonin reuptake inhibitorsUnderlie symptomsUntreated patientsBrain serotoninReuptake inhibitorsSerotonin antagonistsSerotonergic transmissionSingle doseSymptom exacerbationReceptor responsivityTherapeutic effectMetergolinePatientsPlaceboSymptom ratingsSymptomsSuch treatmentSerotoninDisordersPilot resultsDays
1997
Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study
Greenberg B, George M, Martin J, Benjamin J, Schlaepfer T, Altemus M, Wassermann E, Post R, Murphy D. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. American Journal Of Psychiatry 1997, 154: 867-869. PMID: 9167520, DOI: 10.1176/ajp.154.6.867.Peer-Reviewed Original ResearchGenotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder
Karayiorgou M, Altemus M, Galke B, Goldman D, Murphy D, Ott J, Gogos J. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 4572-4575. PMID: 9114031, PMCID: PMC20764, DOI: 10.1073/pnas.94.9.4572.Peer-Reviewed Original ResearchMeSH KeywordsAllelesCatechol O-MethyltransferaseChi-Square DistributionChromosomes, Human, Pair 22FemaleGenotypeHumansMaleObsessive-Compulsive DisorderRisk FactorsSex Factors
1996
Naloxone-Induced Pituitary-Adrenal Activation Does Not Differ in Patients with Depression, Obsessive Compulsive Disorder, and Healthy Controls
Michelson D, Altemus M, Galliven E, Hill L, Greenberg B, Gold P. Naloxone-Induced Pituitary-Adrenal Activation Does Not Differ in Patients with Depression, Obsessive Compulsive Disorder, and Healthy Controls. Neuropsychopharmacology 1996, 15: 207-212. PMID: 8840357, DOI: 10.1016/0893-133x(95)00210-5.Peer-Reviewed Original ResearchConceptsHypothalamic CRH neuronsAdrenocorticotropic hormoneCRH neuronsCortisol secretionElevated urinary free cortisolHypothalamic CRH releaseUrinary free cortisolOpiate antagonist naloxoneEvidence of dysregulationPituitary-adrenal activationAdrenal studiesCRH releaseHormone neuronsAntagonist naloxoneHPA axisObsessive-compulsive disorderDepressed patientsHealthy controlsHypothalamic corticotropinRandomized fashionCentral stimulantsNaloxoneSeparate daysPatientsPsychiatric controlsIntact coding region of the serotonin transporter gene in obsessive‐compulsive disorder
Altemus M, Murphy D, Greenberg B, Lesch K. Intact coding region of the serotonin transporter gene in obsessive‐compulsive disorder. American Journal Of Medical Genetics 1996, 67: 409-411. PMID: 8837711, DOI: 10.1002/(sici)1096-8628(19960726)67:4<409::aid-ajmg16>3.0.co;2-n.Peer-Reviewed Original ResearchBehavioral effects of naloxone infusion in obsessive-compulsive disorder
Keuler D, Altemus M, Michelson D, Greenberg B, Murphy D. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biological Psychiatry 1996, 40: 154-156. PMID: 8793049, DOI: 10.1016/0006-3223(95)00632-x.Peer-Reviewed Original ResearchComparison of obsessions and compulsions in patients with anorexia nervosa and obsessive compulsive disorder
Bastiani A, Altemus M, Pigott T, Rubenstein C, Weltzin T, Kaye W. Comparison of obsessions and compulsions in patients with anorexia nervosa and obsessive compulsive disorder. Biological Psychiatry 1996, 39: 966-969. PMID: 9162209, DOI: 10.1016/0006-3223(95)00306-1.Peer-Reviewed Original ResearchAdolescentAdultAnorexia NervosaCompulsive BehaviorFemaleHumansObsessive BehaviorObsessive-Compulsive DisorderPsychiatric Status Rating ScalesHypervigilance in patients with obsessive‐compulsive disorder
Wiggs C, Martin A, Altemus M, Murphy D. Hypervigilance in patients with obsessive‐compulsive disorder. Anxiety 1996, 2: 123-129. PMID: 9160613, DOI: 10.1002/(sici)1522-7154(1996)2:3<123::aid-anxi3>3.0.co;2-q.Peer-Reviewed Original ResearchMeSH KeywordsAdultArousalAttentionDiscrimination LearningFemaleHumansMaleMental RecallMiddle AgedObsessive-Compulsive DisorderPaired-Associate LearningVerbal LearningConceptsObsessive-compulsive disorderOCD patientsExplicit memory tasksFeature-specific informationRecognition of wordsExplicit memoryMemory taskPriming taskExplicit measuresNormal performanceUnusual wordsSensitive measureMemoryNormal controlsWordsTaskMeasuresHypervigilanceDisordersRecognitionRecallPrimingAttentionFindingsInformationEffects of serotonergic agents on food-restriction-induced hyperactivity
Altemus M, Glowa J, Galliven E, Leong Y, Murphy D. Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacology Biochemistry And Behavior 1996, 53: 123-131. PMID: 8848441, DOI: 10.1016/0091-3057(95)02003-9.Peer-Reviewed Original ResearchConceptsSaline-treated ratsObsessive-compulsive disorderReuptake inhibitorsSerotonin selective reuptake inhibitorsSelective monoamine reuptake inhibitorsSelective reuptake inhibitorsChronic fluoxetine treatmentMonoamine reuptake inhibitorsTryptophan hydroxylase inhibitorCentral serotonergic activityPossible animal modelOCD symptomsFluoxetine treatmentChronic treatmentPharmacological treatmentSerotonergic agentsSerotonergic neurotransmissionSerotonergic activityFood restrictionHydroxylase inhibitorAnimal modelsRunning wheelRatsParachlorophenylalanineAdditional group
1995
Neuropeptides in Anxiety Disorders
ALTEMUS M. Neuropeptides in Anxiety Disorders. Annals Of The New York Academy Of Sciences 1995, 771: 697-707. PMID: 8597442, DOI: 10.1111/j.1749-6632.1995.tb44721.x.Peer-Reviewed Original ResearchAnimalsFemaleHumansHypothalamo-Hypophyseal SystemLactationNeuropeptidesObsessive-Compulsive DisorderPituitary-Adrenal SystemWorking memory as assessed by subject-ordered tasks in patients with obsessive-compulsive disorderxs
Martin A, Wiggs C, Altemus M, Rubenstein C, Murphy D. Working memory as assessed by subject-ordered tasks in patients with obsessive-compulsive disorderxs. Journal Of Clinical And Experimental Neuropsychology 1995, 17: 786-792. PMID: 8557818, DOI: 10.1080/01688639508405167.Peer-Reviewed Original ResearchMeSH KeywordsAdultFemaleHumansMaleMemoryNeuropsychological TestsObsessive-Compulsive DisorderTask Performance and AnalysisConceptsObsessive-compulsive disorderOCD patientsNormal recognition memorySelf-paced taskPrefrontal lobe dysfunctionFocal brain lesionsMemory spanMemory taskRecognition memorySlowed performanceOCD symptomsPrefrontal cortexFunctional brainTaskMemoryBrain lesionsResponse timeStudy of NormalAnxietyRatingsCortexDepressionStudy of patientsDisordersPerformance
1994
Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine
Altemus M, Swedo S, Leonard H, Richter D, Rubinow D, Potter W, Rapoport J. Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine. JAMA Psychiatry 1994, 51: 794-803. PMID: 7524463, DOI: 10.1001/archpsyc.1994.03950100042004.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing hormoneLong-term treatmentObsessive-compulsive disorderCSF levelsHomovanillic acidCSF monoamine metabolite levelsCentral administrationCerebrospinal fluid levelsSignificant decreaseCSF homovanillic acidMonoamine metabolite levelsCerebrospinal fluid neurochemistryCSF oxytocin levelsOpposite behavioral effectsPharmacologic treatmentSomatostatin levelsMonoamine metabolitesPathophysiologic processesFluid levelsBehavioral effectsOxytocin levelsClomipramine hydrochlorideMetabolite levelsDisordersVasopressin
1993
CSF somatostatin in obsessive-compulsive disorder
Altemus M, Pigott T, L'Heureux F, Davis C, Rubinow D, Murphy D, Gold P. CSF somatostatin in obsessive-compulsive disorder. American Journal Of Psychiatry 1993, 150: 460-464. PMID: 8094599, DOI: 10.1176/ajp.150.3.460.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderCSF somatostatinDrug-free outpatientsSerotonin reuptake inhibitorsSpectrum of disordersSubstantial cognitive deficitsMeasurement of somatostatinPredominant symptomReuptake inhibitorsSomatostatin activitySomatostatin levelsBrain contentPatient subgroupsClinical symptomatologyNormal subjectsNormal volunteersSomatostatinPatientsNeuropharmacological agentsExperimental animalsCognitive deficitsCentral administrationDisordersFunctional significance
1992
Abnormalities in the Regulation of Vasopressin and Corticotropin Releasing Factor Secretion in Obsessive-Compulsive Disorder
Altemus M, Pigott T, Kalogeras K, Demitrack M, Dubbert B, Murphy D, Gold P. Abnormalities in the Regulation of Vasopressin and Corticotropin Releasing Factor Secretion in Obsessive-Compulsive Disorder. JAMA Psychiatry 1992, 49: 9-20. PMID: 1370198, DOI: 10.1001/archpsyc.1992.01820010009002.Peer-Reviewed Original Research
1991
Symptoms of eating disorders in patients with obsessive-compulsive disorder
Pigott T, Altemus M, Rubenstein C, Hill J, Bihari K, L'Heureux F, Bernstein S, Murphy D. Symptoms of eating disorders in patients with obsessive-compulsive disorder. American Journal Of Psychiatry 1991, 148: 1552-1557. PMID: 1928472, DOI: 10.1176/ajp.148.11.1552.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAnorexia NervosaBody ImageBody Mass IndexBody WeightBulimiaFeeding and Eating DisordersFemaleHumansMaleObsessive-Compulsive DisorderPersonality InventorySex FactorsConceptsObsessive-compulsive disorderEating Disorder InventoryHealthy comparison subjectsDisorder InventoryComparison subjectsSelf-rating scaleBody dissatisfactionEating AttitudesInteroceptive awarenessDisorder displayInterpersonal distrustMaturity fearsBehavioral dimensionsBulimia nervosaAnorexia nervosaFemale normal subjectsReliable measureMore symptomsDisorders ClinicFemale inpatientsInventoryNervosaPotential overlapDisordersAttitudes